The first triple-receptor agonist, simultaneously activating GIP, GLP-1, and glucagon pathways for maximum weight loss. The third receptor —glucagon — is what sets it apart: it actively increases energy expenditure, boosts resting metabolic rate, and targets liver fat. In the Phase 2 trial (NEJM2023), patients on the 12 mg dose achieved 24.2% body weight reduction in 48 weeks, with 100% losing at least 5%. Sub-study analysis showed up to 86% liver fat reduction. Phase 3 data shows up to 28.7% at 68 weeks — surpassing both semaglutide and tirzepatide. Eat less, metabolize better, burn more — all from one weekly injection. Physician-prescribed, compounded by a licensed 503B pharmacy, HSA/FSA eligible, shipped to your door.
Retatrutide
1mg/0.5mL (2mg)
Select Dosage
$199.00/month
Quantity
- Licensed Physicians
- Free Shipping
- Cancel Anytime
- HSA/FSA Eligible
$199.00/mo per unit. Cancel anytime — no commitments.
As Seen In
The Science
What is Retatrutide?
Retatrutide is a 39-amino-acid, lipidated, once-weekly peptide developed by Eli Lilly as the first true triple-receptor agonist — a single molecule that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is currently advancing through the global Phase 3 TRIUMPH program for obesity and type 2 diabetes, building on landmark Phase 2 data published in the New England Journal of Medicine (2023).
Where semaglutide (Wegovy, Ozempic) acts on a single pathway and tirzepatide (Zepbound, Mounjaro) hits two, retatrutide adds a third lever: glucagon receptor activation, which increases resting energy expenditure and lipolysis. The result in trial subjects was dose-dependent mean weight loss of up to ~24% at 48 weeks — the largest magnitude reported for any incretin-class therapy to date.
24%
Mean body weight reduction at 12 mg over 48 weeks (Phase 2)
3-in-1
Simultaneous GLP-1, GIP, and glucagon receptor activation
~6 days
Elimination half-life supporting once-weekly dosing
Phase 3
Global TRIUMPH program currently enrolling
Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389:514–526.
Why It Matters
Why Retatrutide is different.
Most GLP-1 therapies work by one mechanism — they help you eat less. Retatrutide goes further, pairing appetite suppression (GLP-1) and improved insulin sensitivity (GIP) with an active "burn more" arm (glucagon). In head-to-head context, published Phase 2 numbers place retatrutide ahead of both semaglutide and tirzepatide on total body weight reduction.
Administered once weekly as a subcutaneous injection, retatrutide uses the same standard reconstitution workflow research subjects are already familiar with from tirzepatide: mix the lyophilized peptide with bacteriostatic water, store refrigerated, and follow a predictable 4-week titration ladder starting at 1–2 mg and escalating toward an 8–12 mg maintenance dose.
Compare Treatments
Retatrutide vs. Other Options
| Recommended Retatrutide | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Ozempic/Wegovy) | |
|---|---|---|---|
| Receptor Targets | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Mean Weight Loss (Peak Trial Data) | ~24% | ~21% | ~15% |
| Appetite Suppression | |||
| Improves Insulin Sensitivity | |||
| Increases Energy Expenditure | |||
| Once-Weekly Dosing | |||
| Development Phase | Phase 3 | FDA Approved | FDA Approved |
| Brand Equivalent | Investigational | Zepbound / Mounjaro | Wegovy / Ozempic |
| Requires Prescription |
Benefits of Retatrutide
Significant Weight Reduction
Phase 2 data showed up to ~24% mean body weight loss at 48 weeks, the highest magnitude observed for any incretin therapy to date.
Triple-Receptor Activation
A single weekly dose engages three metabolic pathways at once — GLP-1, GIP, and glucagon — addressing multiple drivers of obesity simultaneously instead of just one.
Powerful Appetite Suppression
GLP-1 agonism quiets food noise, slows gastric emptying, and extends satiety after meals for a natural calorie deficit — without willpower fatigue.
Active Fat-Burning Metabolism
Glucagon receptor activation raises resting energy expenditure and promotes lipolysis — an advantage no other GLP-1 therapy offers.
Better Glycemic Control
Combined GLP-1 and GIP action improves insulin sensitivity and supports healthier blood sugar and lipid profiles across the day.
Once-Weekly Convenience
A ~6-day half-life allows a single subcutaneous injection per week, fitting easily into any routine with no daily pills or protocols.
Is It Right For You?
Who Retatrutide Is For
The Plateaued Loser
Individuals who saw strong early results on semaglutide or tirzepatide but have stalled — and want to break through with a next-generation triple-agonist.
The High-BMI Candidate
Those with significant weight to lose who need the largest-magnitude response available from the incretin class — medically supervised, steadily titrated.
The Metabolic Optimizer
Focused on insulin sensitivity, visceral fat, liver fat, and full-stack metabolic health — not just the number on the scale.
Not sure if Retatrutide is right for you? Our licensed physicians will evaluate your health history and help determine the best treatment plan during your consultation.
The Process
How It Works
01
Complete Online Assessment
Answer a brief health questionnaire about your symptoms, medical history, and wellness goals.
02
Physician Review & Prescription
A licensed physician reviews your assessment and, if appropriate, prescribes a personalized Retatrutide protocol.
03
Delivered to Your Door
Your prescription is filled by our FDA-registered pharmacy and shipped directly to you with everything you need.
04
Monthly Check-ins
Regular follow-ups with your physician to monitor progress, adjust dosing, and optimize your results.
What Our Patients Say
"I'd lost about 30 lbs on tirzepatide and stalled hard. Three months into retatrutide I'm down another 22 lbs and the food noise is completely gone."
-22 lbs in 12 weeks
— M.R., 44, after switching from tirzepatide
"The appetite quieted down the way it did on semaglutide, but my energy actually went up instead of crashing. That's the part I didn't expect."
Sustained energy
— J.P., 38, week 10
"I've been methodical — slow titration, labs every six weeks — and the numbers are moving in every direction I wanted. A1C down, triglycerides down, weight down."
-18 lbs, improved labs
— D.L., 51, week 16
Your Medical Team
Dr. Sarah Chen, MD
Board-Certified Endocrinologist
Specializes in metabolic disorders and longevity medicine with 12+ years of clinical experience.
Dr. James Miller, DO
Internal Medicine & Peptide Therapy
Fellowship-trained in regenerative medicine with expertise in peptide therapy and hormone optimization protocols.
Dr. Priya Patel, MD
Family Medicine & Preventive Care
Focused on patient-centered care and preventive health protocols for over a decade.
Quality & Safety
FDA-Registered Compounding Pharmacy
Every order is filled by a licensed, FDA-registered 503B compounding pharmacy that meets the highest standards of quality, potency, and sterility.
Our pharmacy partners maintain full accreditation from leading regulatory bodies, ensuring your medication is safe, pure, and prepared under strict quality controls.
The Mars Guarantee
If you're not satisfied within 30 days of your purchase, we'll issue a full refund — no questions asked. We stand behind the quality and efficacy of every product we sell.
Get Started Risk-FreeFrequently Asked Questions
Retatrutide is a once-weekly, 39-amino-acid injectable peptide developed by Eli Lilly. It's the first true triple-agonist in its class, activating the GLP-1, GIP, and glucagon receptors simultaneously to drive weight loss, appetite suppression, and improved metabolic health.
Semaglutide (Ozempic, Wegovy) targets one receptor (GLP-1). Tirzepatide (Mounjaro, Zepbound) targets two (GLP-1 and GIP). Retatrutide targets three — adding glucagon receptor activation, which actively increases energy expenditure. In Phase 2, retatrutide outperformed both on total body weight reduction.
Think of it as three levers. GLP-1 helps you eat less by quieting appetite and slowing gastric emptying. GIP helps you use food better by improving insulin sensitivity. Glucagon helps you burn more by raising resting energy expenditure and promoting fat breakdown. Retatrutide pulls all three at once.
In the published Phase 2 trial, subjects at the 12 mg dose lost an average of ~24% of body weight over 48 weeks. Lower doses produced proportionally lower losses. Individual response varies significantly based on starting weight, diet, activity, and titration.
Based on the TRIUMPH Phase 3 protocol, most users start at 1–2 mg weekly for 4 weeks, then escalate in 4-week intervals through 4 mg, 6 mg, 8 mg, and ultimately settle on a maintenance dose between 4 mg and 12 mg. Advanced protocols go to 15 mg. Always escalate on the advice of a clinician.
Retatrutide is a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The lyophilized peptide is reconstituted with bacteriostatic water and stored refrigerated.
The most common are gastrointestinal — nausea, vomiting, diarrhea, constipation — which are dose-dependent and usually transient. Other reported effects include fatigue, headache, mild increases in heart rate, injection-site reactions, and at higher doses, dysesthesia (skin tingling). Starting low and titrating slowly minimizes these.
Not yet. Retatrutide is currently investigational and in Phase 3 clinical trials (the TRIUMPH program). It is available through licensed compounding pharmacies under research and prescription frameworks.
Retatrutide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, active pancreatitis, severe gastrointestinal disease, or pregnancy/breastfeeding. A full medical intake is required before use.
It can. Retatrutide slows gastric emptying and may alter the absorption of oral medications. It may also amplify hypoglycemia when combined with insulin or sulfonylureas. Always share a full medication list during your consultation.
Reconstitute the lyophilized peptide with bacteriostatic water per the instructions provided with your shipment. Store the vial refrigerated at 36–46°F (2–8°C) and use within the stability window specified on the label. Do not freeze.
As with other GLP-1 therapies, appetite typically rebounds and some weight regain is common without sustained lifestyle changes. A gradual taper and a transition plan — diet, activity, sometimes maintenance dosing — help preserve results.
Some users combine retatrutide with complementary peptides (e.g. BPC-157, tesamorelin, sermorelin) for specific goals. Stacking should always be directed by a clinician familiar with the full metabolic picture and monitoring needs.
Orders ship cold-chain with insulated packaging and ice packs, typically overnight or 2-day. You'll receive tracking on dispatch. On arrival, refrigerate immediately.
